AOD-9604
HGH fragment 177-191 (modified)
A lipolytic fragment of growth hormone.
Half-life
~ hours
Mol. weight
1817.1 g/mol
Sequence
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (modified 177-191)
Discussions
0 threads
Overview
AOD-9604 is a modified peptide corresponding to the C-terminal fragment (amino acids 177-191) of human growth hormone, designed to isolate the hormone's lipolytic (fat-releasing) activity from its growth-promoting effects. It is studied for fat-loss without the broader metabolic footprint of full-length HGH.
Mechanism of action
The 177-191 region of HGH is associated with fat metabolism. AOD-9604 is engineered to mimic this lipolytic region to stimulate the breakdown and oxidation of fat while avoiding the IGF-1-mediated growth effects of full-length growth hormone. Clinical development was limited; early trials showed modest effects and the compound was not ultimately approved.
Researched benefits
- Designed to isolate HGH's lipolytic activity
- Targets fat metabolism without full HGH's growth effects
- Studied for fat-loss in preclinical and limited clinical work
Considerations
- Clinical development was discontinued; efficacy in humans is modest
- Not FDA-approved
- Fragment often loses potency vs parent hormone
- Research context only
Key Academic Literature & Studies
Search more in PubMedPeer-reviewed citations and clinical trials evaluating AOD-9604 in scientific literature.
Query PubMed for recent peer-reviewed preclinical and clinical publications on AOD-9604:
View AOD-9604 index on PubMed (NCBI)